Raymond Anderson - 25 Aug 2026 Form 4/A - Amendment Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: Director
Issuer ticker: MNPR
Reported as of: 25 Aug 2026
Net transaction value: -$351,835
SEC form: 4/A - Amendment
Accepted by SEC: 28 Aug 2026, 19:41:10 UTC
Original report date: 27 Aug 2026
Prior SEC filing: 08 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Quan Vu, Attorney-in-fact

Key filing fact

Raymond Anderson filed Form 4/A - Amendment for Monopar Therapeutics (MNPR) on 28 Aug 2026.

Key facts

This page summarizes Raymond Anderson's Form 4/A - Amendment filing for Monopar Therapeutics (MNPR).
7 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Aug 2026, 19:41.

Change

Previous filing in this sequence was filed on 08 Dec 2025.
Current net transaction value: -$351,835.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001362489 Primary reporting owner

Anderson Raymond

Relationship: Director
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Quan Vu, Attorney-in-fact
Signature date: 28 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,402
Change %: +26%
Price: $30.00^*
Shares after: 6,775
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,740
Change %: +26%
Price: $30.00^*
Shares after: 8,515
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Sale

Transaction value: $76,368
Shares: -694
Change %: -8.2%
Price: $110.04
Shares after: 7,821
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1, F4

MNPR transaction

Common Stock

Sale

Transaction value: $71,751
Shares: -646
Change %: -8.3%
Price: $111.07
Shares after: 7,175
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1, F5

MNPR transaction

Common Stock

Sale

Transaction value: $203,716
Shares: -1,802
Change %: -25%
Price: $113.05
Shares after: 5,373
Date: 25 Aug 2026
Ownership: Direct
Footnotes: F1, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: +1,402
Change %: +100%
Price: $0.000000^*
Shares after: 2,803
Date: 25 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,402
Exercise price: $30.00
Footnotes: F1, F2

MNPR transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: +1,740
Change %: +100%
Price: $0.000000^*
Shares after: 3,480
Date: 25 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,740
Exercise price: $30.00
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.

Footnote F2

On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

Footnote F3

On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

Footnote F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

SEC remarks

On August 27, 2026, the reporting person filed a Form 4, which inadvertently omitted two option exercises that were made prior to the reporting person's sale of shares of common stock. Both the option exercises and the sales of common stock were effected pursuant to a Rule 10b5-1 Plan. The prior Form 4 also did not account for Monopar Therapeutics Inc.'s 5 to 1 reverse stock split of its common stock, which was effected August 12, 2024 (the "Reverse Stock Split"). The amount of securities reported on this amended Form 4 have been adjusted to reflect the Reverse Stock Split.